1. Generics Bulletin
  2. >>Leadership

Zentiva Refreshes Senior Leadership Team

Soňa Porubská Takes Over As Global Head Of Corporate Affairs

 
• By Chloe Kent

Zentiva has made some high-profile changes to its senior leadership team in recent weeks. Former general manager of its Czech Republic and Slovakia business Soňa Porubská is taking on a new role as global head of corporate affairs, succeeded by Boris Sananes.

Phone screen with Zentiva logo on pile of drug capsules
Zentiva has welcomed a new global head of corporate affairs • Source: Alamy

After over a decade as general manager of Zentiva’s Czech Republic and Slovakia business, Soňa Porubská has moved to a new position in the global executive team as head of corporate affairs and strategic franchises. Porubská had served in the regional role from December 2011 to January 2022.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

Celltrion Plans Multiple US Biosimilar Launches In An ‘Exciting And Momentous’ Year

 
• By Dave Wallace

With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.

‘Our Commitment Is Serious’: Fresenius Kabi’s CEO Pierluigi Antonelli On Biosimilars And Beyond

 
• By Dean Rudge

Fresenius Kabi is drawing closer to the conclusion of its Vision 2026 strategic roadmap. The company’s CEO, Pierluigi Antonelli, talks to Generics Bulletin about the company’s results so far and how it’s investments in biosimilars, acquisitions and manufacturing is paying off.

IGBA’s Susana Almeida On Consensus Building, Harmonization, And Policy Built On Science – Not Politics

 
• By Urtė Fultinavičiūtė

IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.

More from Generics Bulletin

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

Wockhardt Confirms US Market Exit After Past Challenges

 
• By Adam Zamecnik

Following past challenges on the US market, the Indian pharma player Wockhardt will be shuttering its presence in the country due to commercial reasons.

Biocon Chooses To Settle Over Eylea In US – Will Others Follow?

 
• By Dave Wallace

After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?